Literature DB >> 19147565

Morelloflavone, a biflavonoid, inhibits tumor angiogenesis by targeting rho GTPases and extracellular signal-regulated kinase signaling pathways.

Xiufeng Pang1, Tingfang Yi, Zhengfang Yi, Sung Gook Cho, Weijing Qu, Decha Pinkaew, Ken Fujise, Mingyao Liu.   

Abstract

Morelloflavone, a biflavonoid extracted from Garcinia dulcis, has shown antioxidative, antiviral, and anti-inflammatory properties. However, the function and the mechanism of this compound in cancer treatment and tumor angiogenesis have not been elucidated to date. In this study, we postulated that morelloflavone might have the ability to inhibit angiogenesis, the pivotal step in tumor growth, invasiveness, and metastasis. We showed that morelloflavone could inhibit vascular endothelial growth factor (VEGF)-induced cell proliferation, migration, invasion, and capillary-like tube formation of primary cultured human umbilical vascular endothelial cells in a dose-dependent manner. Morelloflavone effectively inhibited microvessel sprouting of endothelial cells in the mouse aortic ring assay and the formation of new blood microvessels induced by VEGF in the mouse Matrigel plug assay. Furthermore, morelloflavone inhibited tumor growth and tumor angiogenesis of prostate cancer cells (PC-3) in xenograft mouse tumor model in vivo, suggesting that morelloflavone inhibited tumorigenesis by targeting angiogenesis. To understand the underlying mechanism of morelloflavone on the inhibitory effect of tumor growth and angiogenesis, we showed that morelloflavone could inhibit the activation of both RhoA and Rac1 GTPases but have little effect on the activation of Cdc42 GTPase. Additionally, morelloflavone inhibited the phosphorylation and activation of Raf/mitogen-activated protein kinase/extracellular signal-regulated kinase (ERK) kinase/ERK pathway kinases without affecting VEGF receptor 2 activity. Together, our results indicate that morelloflavone exerts antiangiogenic action by targeting the activation of Rho-GTPases and ERK signaling pathways. These findings are the first to reveal the novel functions of morelloflavone in tumor angiogenesis and its molecular basis for the anticancer action.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19147565      PMCID: PMC2662342          DOI: 10.1158/0008-5472.CAN-08-2531

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  45 in total

Review 1.  Rho and Rac take center stage.

Authors:  Keith Burridge; Krister Wennerberg
Journal:  Cell       Date:  2004-01-23       Impact factor: 41.582

Review 2.  Vasculogenesis and angiogenesis.

Authors:  Sybill Patan
Journal:  Cancer Treat Res       Date:  2004

3.  Genotype-dependent expression of endothelial nitric oxide synthase (eNOS) and its regulatory proteins in cultured endothelial cells.

Authors:  Duraisamy Senthil; Muthuswamy Raveendran; Ying H Shen; Budi Utama; Donald Dudley; Jian Wang; Xing Li Wang
Journal:  DNA Cell Biol       Date:  2005-04       Impact factor: 3.311

Review 4.  Raf kinases: oncogenesis and drug discovery.

Authors:  Ralf Schreck; Ulf R Rapp
Journal:  Int J Cancer       Date:  2006-11-15       Impact factor: 7.396

Review 5.  Tumor angiogenesis: therapeutic implications.

Authors:  J Folkman
Journal:  N Engl J Med       Date:  1971-11-18       Impact factor: 91.245

Review 6.  Role and regulation of 90 kDa ribosomal S6 kinase (RSK) in signal transduction.

Authors:  M Frödin; S Gammeltoft
Journal:  Mol Cell Endocrinol       Date:  1999-05-25       Impact factor: 4.102

7.  Inhibition of tumor endothelial ERK activation, angiogenesis, and tumor growth by sorafenib (BAY43-9006).

Authors:  Danielle A Murphy; Sosina Makonnen; Wiem Lassoued; Michael D Feldman; Christopher Carter; William M F Lee
Journal:  Am J Pathol       Date:  2006-11       Impact factor: 4.307

8.  Capsiate, a nonpungent capsaicin-like compound, inhibits angiogenesis and vascular permeability via a direct inhibition of Src kinase activity.

Authors:  Bo-Jeong Pyun; Sun Choi; Yoonji Lee; Tae-Woong Kim; Jeong-Ki Min; Yonghak Kim; Byung-Dong Kim; Jeong-Han Kim; Tae-Yoon Kim; Young-Myeong Kim; Young-Guen Kwon
Journal:  Cancer Res       Date:  2008-01-01       Impact factor: 12.701

9.  Inhibition of MAPK kinase signaling pathways suppressed renal cell carcinoma growth and angiogenesis in vivo.

Authors:  Dan Huang; Yan Ding; Wang-Mei Luo; Stephanie Bender; Chao-Nan Qian; Eric Kort; Zhong-Fa Zhang; Kristin VandenBeldt; Nicholas S Duesbery; James H Resau; Bin Tean Teh
Journal:  Cancer Res       Date:  2008-01-01       Impact factor: 12.701

Review 10.  Rho GTPases in cancer cell biology.

Authors:  Francisco M Vega; Anne J Ridley
Journal:  FEBS Lett       Date:  2008-05-05       Impact factor: 4.124

View more
  29 in total

1.  1'-Acetoxychavicol acetate suppresses angiogenesis-mediated human prostate tumor growth by targeting VEGF-mediated Src-FAK-Rho GTPase-signaling pathway.

Authors:  Xiufeng Pang; Li Zhang; Li Lai; Jing Chen; Yuanyuan Wu; Zhengfang Yi; Jian Zhang; Weijing Qu; Bharat B Aggarwal; Mingyao Liu
Journal:  Carcinogenesis       Date:  2011-03-22       Impact factor: 4.944

2.  Acetyl-11-keto-beta-boswellic acid inhibits prostate tumor growth by suppressing vascular endothelial growth factor receptor 2-mediated angiogenesis.

Authors:  Xiufeng Pang; Zhengfang Yi; Xiaoli Zhang; Bokyung Sung; Weijing Qu; Xiaoyuan Lian; Bharat B Aggarwal; Mingyao Liu
Journal:  Cancer Res       Date:  2009-06-30       Impact factor: 12.701

3.  (-)-Gossypol suppresses the growth of human prostate cancer xenografts via modulating VEGF signaling-mediated angiogenesis.

Authors:  Xiufeng Pang; Yuanyuan Wu; Yougen Wu; Binbin Lu; Jing Chen; Jieqiong Wang; Zhengfang Yi; Weijing Qu; Mingyao Liu
Journal:  Mol Cancer Ther       Date:  2011-03-03       Impact factor: 6.261

4.  Potential Anticancer Agents Characterized from Selected Tropical Plants.

Authors:  Yulin Ren; Esperanza J Carcache de Blanco; James R Fuchs; Djaja D Soejarto; Joanna E Burdette; Steven M Swanson; A Douglas Kinghorn
Journal:  J Nat Prod       Date:  2019-03-04       Impact factor: 4.050

5.  Morelloflavone, a biflavonoid inhibitor of migration-related kinases, ameliorates atherosclerosis in mice.

Authors:  Decha Pinkaew; Nongporn Hutadilok-Towatana; Ba-Bie Teng; Wilawan Mahabusarakam; Ken Fujise
Journal:  Am J Physiol Heart Circ Physiol       Date:  2011-11-04       Impact factor: 4.733

6.  Plumbagin inhibits tumour angiogenesis and tumour growth through the Ras signalling pathway following activation of the VEGF receptor-2.

Authors:  Li Lai; Junchen Liu; Dong Zhai; Qingxiang Lin; Lijun He; Yanmin Dong; Jing Zhang; Binbin Lu; Yihua Chen; Zhengfang Yi; Mingyao Liu
Journal:  Br J Pharmacol       Date:  2012-02       Impact factor: 8.739

Review 7.  Progress in tumor vascular normalization for anticancer therapy: challenges and perspectives.

Authors:  Bingxue Shang; Zhifei Cao; Quansheng Zhou
Journal:  Front Med       Date:  2012-03-31       Impact factor: 4.592

8.  Carvedilol may attenuate liver cirrhosis by inhibiting angiogenesis through the VEGF-Src-ERK signaling pathway.

Authors:  Qian Ding; Xiang-Guo Tian; Yan Li; Qi-Zhi Wang; Chun-Qing Zhang
Journal:  World J Gastroenterol       Date:  2015-08-28       Impact factor: 5.742

9.  Microvesicles secreted from human multiple myeloma cells promote angiogenesis.

Authors:  Yan Liu; Xiao-jian Zhu; Chen Zeng; Pin-hui Wu; Hong-xiang Wang; Zhi-chao Chen; Qiu-bai Li
Journal:  Acta Pharmacol Sin       Date:  2013-12-30       Impact factor: 6.150

10.  MicroRNA-497 and bufalin act synergistically to inhibit colorectal cancer metastasis.

Authors:  Yan-yan Qiu; Qiang Hu; Qing-feng Tang; Wen Feng; Song-jiao Hu; Bo Liang; Wen Peng; Pei-hao Yin
Journal:  Tumour Biol       Date:  2013-12-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.